Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Saved in:
| Title: | Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101) |
|---|---|
| Authors: | Christoph Tausch, Kavitha Däster, Stefanie Hayoz, Zoltan Matrai, Florian Fitzal, Guido Henke, Daniel R. Zwahlen, Günther Gruber, Frank Zimmermann, Mariacarla Andreozzi, Maite Goldschmidt, Alexandra Schulz, Nadia Maggi, Ramon Saccilotto, Martin Heidinger, Andreas Mueller, Ekaterini Christina Tampaki, Vesna Bjelic-Radisic, Ákos Sávolt, Viktor Smanykó, Daniela Hagen, Dieter J. Müller, Michael Gnant, Sibylle Loibl, Pagona Markellou, Inga Bekes, Daniel Egle, Thomas Ruhstaller, Simone Muenst, Sherko Kuemmel, Conny Vrieling, Rok Satler, Charles Becciolini, Susanne Bucher, Christian Kurzeder, Colin Simonson, Peter M. Fehr, Natalie Gabriel, Robert Maráz, Dimitri Sarlos, Konstantin J. Dedes, Cornelia Leo, Gilles Berclaz, Hisham Fansa, Christopher Hager, Klaus Reisenberger, Christian F. Singer, Giacomo Montagna, Roland Reitsamer, Jelena Winkler, Giang Thanh Lam, Mathias K. Fehr, Tatiana Naydina, Magdalena Kohlik, Karine Clerc, Valerijus Ostapenko, Loïc Lelièvre, Jörg Heil, Michael Knauer, Walter Paul Weber |
| Source: | Breast Cancer Res Treat Breast cancer research and treatment, vol. 201, no. 2, pp. 215-225 |
| Publisher Information: | Springer Science and Business Media LLC, 2023. |
| Publication Year: | 2023 |
| Subject Terms: | Europe, Receptor, ErbB-2, Humans, Female, Breast Neoplasms, Prospective Studies, Breast, Middle Aged, Clinical Trial, Breast Neoplasms/drug therapy, Breast Neoplasms/epidemiology, Breast Neoplasms/metabolism, Neoadjuvant Therapy, Breast/pathology, Europe/epidemiology, Receptor, ErbB-2/metabolism, Breast cancer surgery, Clinically node-positive, Neoadjuvant chemotherapy, Neoadjuvant systemic therapy, TAXIS trial, Tailored axillary surgery, 3. Good health |
| Description: | Purpose The aim of this study was to evaluate clinical practice heterogeneity in use of neoadjuvant systemic therapy (NST) for patients with clinically node-positive breast cancer in Europe. Methods The study was preplanned in the international multicenter phase-III OPBC-03/TAXIS trial (ClinicalTrials.gov Identifier: NCT03513614) to include the first 500 randomized patients with confirmed nodal disease at the time of surgery. The TAXIS study’s pragmatic design allowed both the neoadjuvant and adjuvant setting according to the preferences of the local investigators who were encouraged to register eligible patients consecutively. Results A total of 500 patients were included at 44 breast centers in six European countries from August 2018 to June 2022, 165 (33%) of whom underwent NST. Median age was 57 years (interquartile range [IQR], 48–69). Most patients were postmenopausal (68.4%) with grade 2 and 3 hormonal receptor-positive and human epidermal growth factor receptor 2-negative breast cancer with a median tumor size of 28 mm (IQR 20–40). The use of NST varied significantly across the countries (p Conclusion Substantial heterogeneity in the use of NST with HR+/HER2-breast cancer exists in Europe. While stringent guidelines are available for its use in triple-negative and HER2+ breast cancer, there is a need for the development of and adherence to well-defined recommendations for HR+/HER2-breast cancer. |
| Document Type: | Article Other literature type |
| File Description: | application/pdf |
| Language: | English |
| ISSN: | 1573-7217 0167-6806 |
| DOI: | 10.1007/s10549-023-06999-9 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/37355526 https://serval.unil.ch/notice/serval:BIB_3FFC045E0929 https://serval.unil.ch/resource/serval:BIB_3FFC045E0929.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_3FFC045E09295 |
| Rights: | CC BY |
| Accession Number: | edsair.doi.dedup.....8d4cf07804708350568edfa1545c0c74 |
| Database: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Purpose The aim of this study was to evaluate clinical practice heterogeneity in use of neoadjuvant systemic therapy (NST) for patients with clinically node-positive breast cancer in Europe. Methods The study was preplanned in the international multicenter phase-III OPBC-03/TAXIS trial (ClinicalTrials.gov Identifier: NCT03513614) to include the first 500 randomized patients with confirmed nodal disease at the time of surgery. The TAXIS study’s pragmatic design allowed both the neoadjuvant and adjuvant setting according to the preferences of the local investigators who were encouraged to register eligible patients consecutively. Results A total of 500 patients were included at 44 breast centers in six European countries from August 2018 to June 2022, 165 (33%) of whom underwent NST. Median age was 57 years (interquartile range [IQR], 48–69). Most patients were postmenopausal (68.4%) with grade 2 and 3 hormonal receptor-positive and human epidermal growth factor receptor 2-negative breast cancer with a median tumor size of 28 mm (IQR 20–40). The use of NST varied significantly across the countries (p Conclusion Substantial heterogeneity in the use of NST with HR+/HER2-breast cancer exists in Europe. While stringent guidelines are available for its use in triple-negative and HER2+ breast cancer, there is a need for the development of and adherence to well-defined recommendations for HR+/HER2-breast cancer. |
|---|---|
| ISSN: | 15737217 01676806 |
| DOI: | 10.1007/s10549-023-06999-9 |